Ann Surg Oncol (2025) 32:2612–2613
https://doi.org/10.1245/s10434-025-16952-3

Annals of
SURGICAL ONCOLOGY
OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY

ASO VISUAL ABSTRACT

ASO Visual Abstract: Risk of Surgical Overtreatment in cN1 Breast Cancer Patients Who Become ypN0 After Neoadjuvant Chemotherapy: SLNB Versus TAD

Alison Laws, MD, MPH, FRCSC[1,2,3,4], Saskia Leonard, MD[5], Julie Vincuilla, MPH[1], Tonia Parker, BS[1], Olga Kantor, MD, MS[1,2,3], Elizabeth A. Mittendorf, MD, PhD, MHCM[1,2,3], Anna Weiss, MD[6,7], and Tari A. King, MD[1,2,3]

[1]Division of Breast Surgery, Brigham and Women's Hospital, Boston, MA; [2]Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA; [3]Harvard Medical School, Boston, MA; [4]Present Address: Department of Surgery, University of Calgary, Calgary, AB, Canada; [5]John A. Burns School of Medicine, University of Hawaii, Honolulu, HI; [6]Department of Surgery, University of Rochester Medical Center, Rochester, NY; [7]Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY

Among cN1 breast cancer patients who experience a nodal pathologic complete response after neoadjuvant chemotherapy, both sentinel lymph node biopsy and targeted axillary dissection were associated with technical failures, leading to overtreatment with axillary lymph node dissection in approximately 15% of patients (https://doi.org/10.1245/s10434-024-16625-7).

This work was presented as a poster at the June 2023 annual meeting of the American Society of Clinical Oncology, Chicago, IL, USA.

© Society of Surgical Oncology 2025

Published online: 3 February 2025

A. Laws, MD, MPH, FRCSC
T. A. King, MD
e-mail: tking7@bwh.harvard.edu



FUNDING No sources of funding were used to assist in the preparation of this study.

DISCLOSURE Elizabeth A. Mittendorf reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via an SU2C grant) and Gilead. She also reports research funding from Susan Komen for the Cure, for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. Tari A. King reports speaker honoraria for Exact Sciences; compensated service on the FES Steering Committee and GE Healthcare; and compensated service as faculty for PrecisCa cancer information service. Alison Laws, Saskia Leonard, Julie Vincuilla, Tonia Parker, Olga Kantor, and Anna Weiss declare no conflicts of interest that may be relevant to the contents of this study.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.